Neo Kuma Ventures - aVenture Asset Manager Research
Neo Kuma Ventures
Operating Status: Operating
Europe's pioneering psychedelic healthcare investment fund with a robust portfolio.
Location
London, Greater London, GB
Founded
2020
Neo Kuma Ventures is Europe's pioneering venture capital firm dedicated exclusively to psychedelic healthcare investments. The firm focuses on early-stage companies that are at the forefront of clinical research in psychedelic therapies, aiming to redefine patient care standards. Neo Kuma Ventures typically invests in Seed and Series A rounds, supporting companies that are developing breakthrough treatments for mental health conditions.
Notable portfolio companies include Fluence, Journey Clinical, and Tripp, which have collectively raised significant funding to advance their innovative therapies. Key partners at Neo Kuma Ventures bring extensive expertise in both venture capital and the healthcare sector, ensuring strategic guidance and support for their portfolio companies. The firm’s investment philosophy centers on empowering the use of psychedelic therapies to address the root causes of mental illness, offering unique value-add services such as industry connections and specialized knowledge in psychedelic healthcare.
Neo Kuma Ventures - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies3
Current Portfolio Count3
Top Investment Stages
Seed2 (66.7%)
Series A1 (33.3%)
Stage Mix
Seed 67%Series A 33%
Concentration shown as share of disclosed investments by stage.
